Abstract 172P
Background
Pancreatic cancer is a disease with poor prognosis. Stereotactic body radiation therapy (SBRT) is emerging hope to achieve better resectability and local control. Pancreatic cancer treatment results are currently poorly predicted by the best clinical prediction algorithms. Through quantitative imaging analysis, radiomics and dynamic imaging characteristics can offer data on clinical outcomes and build clinical models based on imaging phenotypes or radiomics signatures. The objective of this pilot study was to analyze the association of CT based radiomic features with overall survival (OS) in pancreatic cancer patients treated with SBRT.
Methods
Ten patients of borderline resectable and locally advanced pancreatic cancer were included. All patients received neoadjuvant chemotherapy followed by SBRT and further chemotherapy and then assessed for surgery. Using pyRadiomics, radiomic features of gross tumour volume were extracted using contrast enhanced planning CT images acquired during SBRT planning. All the statistical analysis was performed using R software. Survival rates were analyzed using Kaplan-Meier survival curves.
Results
Three of the 10 patients were resected. Median follow-up was 15 months (range,5-24 months), median OS was 25 months. A total of 851 radiomic features [shape, first order, gray-level co-occurrence matrix (GLCM); grey level size zone matrix (GLSZM), gray-level distance zone matrix (GLDZM), grey level run length matrix (GLRLM) and grey level zone length matrix (GLZLM), gray-level co-occurrence matrix (GLCM); the neighborhood gray-level different matrix (NGLDM)] were extracted. Based on the radiomics score, patients were stratified into low and high risk categories.
Conclusions
This pilot study highlights the potential of CT-based radiomic features in predicting survival in patients with pancreatic cancer treated with chemotherapy followed by SBRT. The identified radiomic features, along with clinical parameters, offer valuable prognostic information that can aid in treatment decision-making and patient counseling. However, a larger number of patients are required to validate the results.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract
63P - The impact of disruption of melatonin secretion on the structural-functional changes of the microbiome and the role of the melatonin-microbiome axis in the initiation of carcinogenesis
Presenter: Alexandre Tavartkiladze
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Acidosis induces ferroptosis of breast cancer via ZFAND5/SLC3A2 axis with the synergistic effect of metformin and facilitates M1 macrophage polarization
Presenter: Hanchu Xiong
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Transmembrane distribution of phosphatidylethanolamine in plasma membrane of ovarian cancer cells under conditions mimicking tumor microenvironment
Presenter: Darya Savenkova
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma
Presenter: Liam Wilson
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma
Presenter: Aline Atallah
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Integrated OMIC analysis reveals arginine and proline metabolism plays critical role in hypoxia-induced oral squamous cell carcinoma
Presenter: Avinash Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Individualising methotrexate dose based on MTHFR gene polymorphisms in acute lymphoblastic leukemia
Presenter: Meher Konatam
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer
Presenter: Sandro Surmava
Session: Cocktail & Poster Display session
Resources:
Abstract